CFDE Data Portal | Search CIDECP1

	Label	Description
	CIDECP1 Gene (Entity type)	ENSG00000186162 - CIDEC pseudogene 1
	GSE169356 ivermectin prostate gland 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE169356 FOXA1 inhibition prostate gland Ivermectin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE171692 FXN knockdown 1 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE228017 parthenolide 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 4 v 9 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE151090 verteporfin 2 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE236228 penfluridol 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE147876 GSE147877 enzalutamide MR42D 4 v 7 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE239844 crizotinib 6 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS

CIDECP1

ENSG00000186162 - CIDEC pseudogene 1

GSE169356 ivermectin prostate gland 0 v 1 human up

A Gene Set from LINCS

GSE169356 FOXA1 inhibition prostate gland Ivermectin 0 v 1 human up

A Gene Set from LINCS

GSE171692 FXN knockdown 1 v 0 human up

A Gene Set from LINCS

GSE228017 parthenolide 0 v 1 human up

A Gene Set from LINCS

GSE239844 crizotinib 4 v 9 human dn

A Gene Set from LINCS

GSE151090 verteporfin 2 v 4 human up

A Gene Set from LINCS

GSE236228 penfluridol 0 v 1 human up

A Gene Set from LINCS

GSE147876 GSE147877 enzalutamide MR42D 4 v 7 human up

A Gene Set from LINCS

GSE239844 crizotinib 6 v 0 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.